Presence of human papillomavirus 16 in acral Bowen disease as a predictor of a less efficacious response to photodynamic therapy: a retrospective case series of nine patients

Methyl aminolevulinate photodynamic therapy for Bowen's disease on the fingers—Is monotherapy sufficiently effective?

“…To the best of our knowledge, HPV39 positivity has not been previously reported in BD. A recent case series indicated that the presence of HPV16 in acral BD could be a predictor for a reduced response to PDT 8 . The HPV16‐positive patient in this series, whose BD displayed locally aggressive growth, showed no response to PDT.…”

“…A recent case series indicated that the presence of HPV16 in acral BD could be a predictor for a reduced response to PDT. 8 The HPV16-positive patient in this series, whose BD displayed locally aggressive growth, showed no response to PDT. However, no overall correlation between HPV status and response to PDT was found in this case series.…”

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

“…Forty-three studies, enrolling a total of 1943 BD lesions and 282 SCC lesions between 1994 and 2019, were used for quantitative analysis. Thirty-two studies 1,2,5,6,11,15–41 used red light, whereas 9 studies 4,42–49 used laser. Twenty-four studies 3,4,6,16,21,28,31–38,40–42,44–50 used aminolevulinic acid (ALA), and 18 studies 1,2,5,11,15–19,22–27,29,30,39 used methyl aminolevulinate (MAL) as a photosensitizer (see Supplemental Digital Content 2 , Table S2, http://links.lww.com/DSS/B13).…”

“…Thirty-two studies 1,2,5,6,11, used red light, whereas 9 studies 4,42-49 used laser. Twenty-four studies 3,4,6,16,21,28,[31][32][33][34][35][36][37][38][40][41][42][44][45][46][47][48][49][50] used aminolevulinic acid (ALA), and 18 studies 1,2,5,11,[15][16][17][18][19][22][23][24][25][26][27]29,30,39 used methyl aminolevulinate (MAL) as a photosensitizer (see Supplemental Digital Content 2, Table S2, http://links.lww.com/DSS/ B13). Excluding studies that reported occlusion time as range (n 5 9) and mean occlusion time of 3.53 (SD 5 1.99) and 6.11 (SD 5 5.79) hours were found for BD and SCC, respectively.…”

“…Twenty studies 3,5,11,15,17,18,21,31,32,[34][35][36][37][42][43][44]46,47,49,50 reported predominantly small BD lesions, whereas 9 studies 4,20,23,[25][26][27]34,45,48 reported predominantly large BD lesions. Eighteen studies reported BD primarily located on the extremities, 2,5,6,18,19,21,25,29,[31][32][33][34][35][36][37]42,44,47 and 7 studies 3,11,[15][16]…”